This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FPR1 / N-formyl peptide receptor 1 · Western blot design guide
Design a Western Blot for FPR1
Real validated FPR1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-FPR1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
FPR1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~38.4 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Bone marrow (IHC candidate; verify WB) | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Glycosylated + Phosphorylated | |
| Caveat | Peptide-blocking control | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated FPR1 Western Blot Protocols
The A02509 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | lysates from K562 cells, (catalog A02509) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | the synthesized peptide (catalog A02509) |
| Primary antibody | A02509; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected FPR1 Western Blot Band Size?
FPR1 is predicted at 38.4 kDa; its N-linked glycans could affect migration, but no empirical band or demonstrated shift is supplied.
| Band near 38.4 kDa | Consistent with the predicted FPR1 mass, pending identity controls |
| Band above 38.4 kDa | N-linked glycans at Asn4 or Asn10 could affect migration; the shift is unverified |
| Diffuse band near the expected region | Variable glycosylation is possible but has not been shown to cause a smear |
| Weak or absent lysate band | Recovery of this multi-pass membrane receptor may be poor |
💡Expected FPR1 appearanceFPR1 has a predicted mass of 38.4 kDa and no supplied empirical band size; assess any candidate band with peptide competition or an independent antibody.
| Predicted FPR1 mass | Places the unmodified protein near 38.4 kDa |
| N-linked glycosylation at Asn4 | Could alter apparent size; the magnitude is unknown |
| N-linked glycosylation at Asn10 | Could alter apparent size; the magnitude is unknown |
| Glycan occupancy at Asn4 and Asn10 | Variation could broaden migration, but no visible effect is established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | FPR1 is a multi-pass membrane protein that may be poorly recovered | Check membrane extraction and include a membrane fraction |
| Band higher than expected | N-linked glycans at Asn4 or Asn10 are a possible contributor | Compare matched untreated and deglycosylated samples and confirm identity |
| Band lower than expected | Band identity or glycan occupancy is uncertain | Use peptide competition or an independent antibody; compare deglycosylated samples |
| Broad smear instead of sharp band | Variable N-linked glycosylation is possible but unproven | Compare matched untreated and deglycosylated samples |
| Multiple bands | The supplied record lists one isoform, so band identities are unresolved | Use peptide competition and an independent antibody |
| Weak or no signal | Poor recovery of membrane-localized FPR1 is possible | Check membrane enrichment and extraction efficiency |
Experiment evidence
Western blot images showing FPR1 band
A02509 · FPR1
A02509 · FPR1
A02509-3 · FPR1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for FPR1 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for FPR1 in Western blot, you can use bone marrow tissue, the HPA positive sample.
Positive control: Bone marrow (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: FPR1 is a multi-pass membrane protein, so membrane-enriched lysate may improve detection.
HPA tissue expression evidence for FPR1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | hematopoietic cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Caudate | glial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced FPR1 Western Blot Tips
Deeper troubleshooting and optimisation questions for FPR1, answered from its protein features.
How should FPR1 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Should alternative FPR1 isoforms explain multiple bands?
Isoforms · Only one isoform is supplied, with no alternative sequence. Do not assign additional bands to isoforms on this evidence; assess them with antibody specificity controls and the listed modifications in mind.
Could glycosylation affect FPR1 band interpretation?
PTM · UniProt lists N-linked glycosylation at Asn4 and Asn10. These sites make glycosylation relevant when assessing band mobility, but their presence alone does not establish a visible shift. Compare the pattern with an appropriate glycosylation-control experiment if mobility is in question.
UniProt lists phosphoserine at 328, 332 and 338, and phosphothreonine at 329, 331, 334, 336 and 339. These are UniProt coordinates; paper or antibody numbering may differ. Keep sample conditions consistent when comparing phosphorylation-sensitive signals. The listed sites alone do not predict a visible band shift.
UniProt lists phosphoserine at 328, 332 and 338, and phosphothreonine at 329, 331, 334, 336 and 339. These are UniProt coordinates; paper or antibody numbering may differ. Keep sample conditions consistent when comparing phosphorylation-sensitive signals. The listed sites alone do not predict a visible band shift.
Does this guide establish induction of FPR1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for FPR1 Western blot?
Transfer · FPR1 is a multi-pass cell-membrane protein. Check transfer efficiency by examining both the membrane signal and protein left in the gel, and optimize conditions for your setup. The supplied features do not identify a single preferred transfer method.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02509 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How might ligand exposure affect FPR1 quantitation?
Quantitation · FPR1 internalizes in the presence of fMLP, TAFA4 and CTSG. Keep ligand exposure and collection conditions consistent, and distinguish total-cell measurements from membrane-fraction measurements when comparing samples.
How should FPR1 bands be compared with its predicted mass?
Interpretation · The predicted mass is 38.4 kDa, and no observed band size is supplied. Use 38.4 kDa as a reference, but do not assign a band by size alone. The listed modifications do not establish a visible shift or explain any difference from the calculated mass.
Check antibody specificity before assigning an unexpected band. FPR1 has two listed N-linked glycosylation sites, eight listed phosphorylation sites and one disulfide bond; these features are candidates for follow-up experiments, not proof of any particular band identity or mobility shift.
No. The supplied microbial-infection annotation says Staphylococcus aureus CHIPS interacts with and blocks FPR1, potentially inhibiting the immune response. It does not report increased FPR1 abundance. Keep infection and CHIPS exposure conditions explicit when interpreting samples.
Check antibody specificity before assigning an unexpected band. FPR1 has two listed N-linked glycosylation sites, eight listed phosphorylation sites and one disulfide bond; these features are candidates for follow-up experiments, not proof of any particular band identity or mobility shift.
No. The supplied microbial-infection annotation says Staphylococcus aureus CHIPS interacts with and blocks FPR1, potentially inhibiting the immune response. It does not report increased FPR1 abundance. Keep infection and CHIPS exposure conditions explicit when interpreting samples.
Boster reagents
FPR1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-FPR1/Fpr Antibody
Cat # A02509
Real WB data
Anti-FPR1 (I207) Antibody
Cat # A02509-3
Both listed anti-FPR1 antibodies report human, mouse, and rat reactivity and include WB images. A02509 shows K562 lysate with a peptide-blocked lane; A02509-3 shows Jurkat, Raw264.7, and PC12 lysates at 1:500. These images document tested samples, not universal performance.
Which to pick: Choose A02509 if the K562 image and peptide-blocking comparison match your needs. Choose A02509-3 if its Jurkat, Raw264.7, or PC12 WB examples at 1:500 are more relevant. Both report the same species reactivity; assess performance in your own samples.
Source: BosterBio FPR1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P21462.
- Human Protein Atlas. FPR1 tissue expression.
- PMC7576028 — target-verified WB comparison
- PMC4950242 — target-verified WB comparison
- PMC3897705 — target-verified WB comparison